# A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

> **NCT03736785** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 399 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** LY3209590
- **DRUG:** Insulin Degludec

## Key facts

- **NCT ID:** NCT03736785
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-15
- **Primary completion:** 2020-02-18
- **Final completion:** 2020-02-18
- **Target enrollment:** 399 (ACTUAL)
- **Last updated:** 2021-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03736785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03736785, "A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03736785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*